chipseq data Search Results


chipseq data  (Epigenomics ag)
90
Epigenomics ag chipseq data
Chipseq Data, supplied by Epigenomics ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chipseq data/product/Epigenomics ag
Average 90 stars, based on 1 article reviews
chipseq data - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
chipseq data  (Active Motif)
90
Active Motif chipseq data
A The distribution of average promoter <t>DNA</t> methylation for all genes, JARID2 binding site (JBS)genes, LE50 and LE70 genes in primary (P) and recurrent (R) GBM tumors from all patients (top) and once separated into Down (middle) and Up (bottom) responders. B The proportion of differentially methylated promoters (DMP) between primary and matched recurrent GBM. C The average change in methylation between primary and matched recurrent tumors for the DMP from panel B . D The proportion of single GBM cell promoters that have different methylation status. E The proportion of promoters with the H3K27me3 mark in nine patient GBMs. F The proportion of JBSgene promoters that <t>had</t> <t>EZH2</t> bound according to ChIPseq of paired patient samples from an Up and a Down responder. G The proportion of promoters with a specific change in EZH2 occupancy that belonged to each gene set
Chipseq Data, supplied by Active Motif, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chipseq data/product/Active Motif
Average 90 stars, based on 1 article reviews
chipseq data - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
chipseq and data processing  (Active Motif)
90
Active Motif chipseq and data processing
A The distribution of average promoter <t>DNA</t> methylation for all genes, JARID2 binding site (JBS)genes, LE50 and LE70 genes in primary (P) and recurrent (R) GBM tumors from all patients (top) and once separated into Down (middle) and Up (bottom) responders. B The proportion of differentially methylated promoters (DMP) between primary and matched recurrent GBM. C The average change in methylation between primary and matched recurrent tumors for the DMP from panel B . D The proportion of single GBM cell promoters that have different methylation status. E The proportion of promoters with the H3K27me3 mark in nine patient GBMs. F The proportion of JBSgene promoters that <t>had</t> <t>EZH2</t> bound according to ChIPseq of paired patient samples from an Up and a Down responder. G The proportion of promoters with a specific change in EZH2 occupancy that belonged to each gene set
Chipseq And Data Processing, supplied by Active Motif, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chipseq and data processing/product/Active Motif
Average 90 stars, based on 1 article reviews
chipseq and data processing - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
histone chipseq data profiling histone modification  (Epigenomics ag)
90
Epigenomics ag histone chipseq data profiling histone modification
A The distribution of average promoter <t>DNA</t> methylation for all genes, JARID2 binding site (JBS)genes, LE50 and LE70 genes in primary (P) and recurrent (R) GBM tumors from all patients (top) and once separated into Down (middle) and Up (bottom) responders. B The proportion of differentially methylated promoters (DMP) between primary and matched recurrent GBM. C The average change in methylation between primary and matched recurrent tumors for the DMP from panel B . D The proportion of single GBM cell promoters that have different methylation status. E The proportion of promoters with the H3K27me3 mark in nine patient GBMs. F The proportion of JBSgene promoters that <t>had</t> <t>EZH2</t> bound according to ChIPseq of paired patient samples from an Up and a Down responder. G The proportion of promoters with a specific change in EZH2 occupancy that belonged to each gene set
Histone Chipseq Data Profiling Histone Modification, supplied by Epigenomics ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/histone chipseq data profiling histone modification/product/Epigenomics ag
Average 90 stars, based on 1 article reviews
histone chipseq data profiling histone modification - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
chipseq data for resting cd4+ t cells  (Epigenomics ag)
90
Epigenomics ag chipseq data for resting cd4+ t cells
A The distribution of average promoter <t>DNA</t> methylation for all genes, JARID2 binding site (JBS)genes, LE50 and LE70 genes in primary (P) and recurrent (R) GBM tumors from all patients (top) and once separated into Down (middle) and Up (bottom) responders. B The proportion of differentially methylated promoters (DMP) between primary and matched recurrent GBM. C The average change in methylation between primary and matched recurrent tumors for the DMP from panel B . D The proportion of single GBM cell promoters that have different methylation status. E The proportion of promoters with the H3K27me3 mark in nine patient GBMs. F The proportion of JBSgene promoters that <t>had</t> <t>EZH2</t> bound according to ChIPseq of paired patient samples from an Up and a Down responder. G The proportion of promoters with a specific change in EZH2 occupancy that belonged to each gene set
Chipseq Data For Resting Cd4+ T Cells, supplied by Epigenomics ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chipseq data for resting cd4+ t cells/product/Epigenomics ag
Average 90 stars, based on 1 article reviews
chipseq data for resting cd4+ t cells - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
chipseq data on cd14þ monocytes and dermal fibroblasts  (Broad Institute Inc)
90
Broad Institute Inc chipseq data on cd14þ monocytes and dermal fibroblasts
A The distribution of average promoter <t>DNA</t> methylation for all genes, JARID2 binding site (JBS)genes, LE50 and LE70 genes in primary (P) and recurrent (R) GBM tumors from all patients (top) and once separated into Down (middle) and Up (bottom) responders. B The proportion of differentially methylated promoters (DMP) between primary and matched recurrent GBM. C The average change in methylation between primary and matched recurrent tumors for the DMP from panel B . D The proportion of single GBM cell promoters that have different methylation status. E The proportion of promoters with the H3K27me3 mark in nine patient GBMs. F The proportion of JBSgene promoters that <t>had</t> <t>EZH2</t> bound according to ChIPseq of paired patient samples from an Up and a Down responder. G The proportion of promoters with a specific change in EZH2 occupancy that belonged to each gene set
Chipseq Data On Cd14þ Monocytes And Dermal Fibroblasts, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chipseq data on cd14þ monocytes and dermal fibroblasts/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
chipseq data on cd14þ monocytes and dermal fibroblasts - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
shrna kd chipseq data  (Novogene)
86
Novogene shrna kd chipseq data
A The distribution of average promoter <t>DNA</t> methylation for all genes, JARID2 binding site (JBS)genes, LE50 and LE70 genes in primary (P) and recurrent (R) GBM tumors from all patients (top) and once separated into Down (middle) and Up (bottom) responders. B The proportion of differentially methylated promoters (DMP) between primary and matched recurrent GBM. C The average change in methylation between primary and matched recurrent tumors for the DMP from panel B . D The proportion of single GBM cell promoters that have different methylation status. E The proportion of promoters with the H3K27me3 mark in nine patient GBMs. F The proportion of JBSgene promoters that <t>had</t> <t>EZH2</t> bound according to ChIPseq of paired patient samples from an Up and a Down responder. G The proportion of promoters with a specific change in EZH2 occupancy that belonged to each gene set
Shrna Kd Chipseq Data, supplied by Novogene, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/shrna kd chipseq data/product/Novogene
Average 86 stars, based on 1 article reviews
shrna kd chipseq data - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

Image Search Results


A The distribution of average promoter DNA methylation for all genes, JARID2 binding site (JBS)genes, LE50 and LE70 genes in primary (P) and recurrent (R) GBM tumors from all patients (top) and once separated into Down (middle) and Up (bottom) responders. B The proportion of differentially methylated promoters (DMP) between primary and matched recurrent GBM. C The average change in methylation between primary and matched recurrent tumors for the DMP from panel B . D The proportion of single GBM cell promoters that have different methylation status. E The proportion of promoters with the H3K27me3 mark in nine patient GBMs. F The proportion of JBSgene promoters that had EZH2 bound according to ChIPseq of paired patient samples from an Up and a Down responder. G The proportion of promoters with a specific change in EZH2 occupancy that belonged to each gene set

Journal: Genome Biology

Article Title: IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy

doi: 10.1186/s13059-024-03172-3

Figure Lengend Snippet: A The distribution of average promoter DNA methylation for all genes, JARID2 binding site (JBS)genes, LE50 and LE70 genes in primary (P) and recurrent (R) GBM tumors from all patients (top) and once separated into Down (middle) and Up (bottom) responders. B The proportion of differentially methylated promoters (DMP) between primary and matched recurrent GBM. C The average change in methylation between primary and matched recurrent tumors for the DMP from panel B . D The proportion of single GBM cell promoters that have different methylation status. E The proportion of promoters with the H3K27me3 mark in nine patient GBMs. F The proportion of JBSgene promoters that had EZH2 bound according to ChIPseq of paired patient samples from an Up and a Down responder. G The proportion of promoters with a specific change in EZH2 occupancy that belonged to each gene set

Article Snippet: EZH2, and matched input control DNA, ChIPseq data was created from samples in our Discovery cohort by Active Motif (Carlsbad, CA).

Techniques: DNA Methylation Assay, Binding Assay, Methylation